ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

NCT02848274 · tracked via the Priya Life Science China tracker

Sponsor

Stanford University

Phase

Observational

Started

2016-10

Last updated

2025-10-22

Condition(s) studied

Mycosis FungoidesNon-Hodgkin's Lymphoma

Study summary

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria * Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center * Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available Exclusion Criteria * Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage * Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center * Exclude one-time consultation type of new patients.

Primary outcome measure(s)

Overall survival (OS) — date of diagnosis to death from any cause, up to two years

Trial sites (13)

Facility	City	Region	Status
City of Hope	Duarte	California	Recruiting
Stanford University, School of Medicine	Palo Alto	California	Recruiting
University of Iowa	Iowa City	Iowa	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	Recruiting
University of Pittsburg	Pittsburgh	Pennsylvania	Recruiting
University of Texas Southwestern	Dallas	Texas	Recruiting
University of Utah Hospital	Salt Lake City	Utah	Recruiting
Hospital Italiano de Buenos Aires	Buenos Aires	Argentina	Recruiting
Peter MacCallum Cancer Center,	Melbourne	Australia	Recruiting
University of Sao Paulo Medical School	São Paulo	Brazil	Recruiting
Peking University First Hospital	Beijing	China	Recruiting
The University of Tokyo	Tokyo	Japan	Recruiting
University Hospitals Birmingham	Birmingham	United Kingdom	Recruiting

More Stanford University trials in China

Mental Health Support Interventions for Mothers of Infants and Young Children Starting soon

Other trials for the same condition

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma Active, not recruiting

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02848274 on ClinicalTrials.gov ↗ ← All trials in China